TY - JOUR T1 - Corticosteroids in Covid-19: One size does not fit all JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00224-2021 SP - 2100224 AU - Athena Gogali AU - Chris Kyriakopoulos AU - Konstantinos Kostikas Y1 - 2021/01/01 UR - http://erj.ersjournals.com/content/early/2021/02/04/13993003.00224-2021.abstract N2 - Edalatifard and colleagues, in a single-blind randomised controlled clinical trial showed that methylprednisolone pulse administration (250 mg·day−1 intravenously for 3 days) to hospitalised, not intubated patients with severe coronavirus disease 2019 (COVID-19), significantly improved survival and duration of recovery compared to standard care; the effect was more prominent in patients receiving non-invasive ventilation and reservoir mask support [1].Organising Pneumonia and Acute Fibrinous and Organising Pneumonia has been reported as the predominant pattern in pathological samples of COVID-19 patients. Critically ill COVID-19 patients may benefit even more from higher corticosteroid doses. ER -